The role of co-crystals in pharmaceutical design

Trends in Pharmacological Sciences

Volumn 34, Issue 3, 2013, Pages 185-193

  Steed, Jonathan W ^a  

^a DURHAM UNIVERSITY   (United Kingdom)

Author keywords

formulation; polymorph; solid form; solubility; solvate

Indexed keywords

ACTIVE PHARMACEUTICAL INGREDIENT; DRUG; FLUOXETINE; INSULIN; MELOXICAM; PIROXICAM; UNCLASSIFIED DRUG;

BULK DENSITY; CO CRYSTAL; COMPLEX FORMATION; COMPRESSIBILIY; CRYSTAL; CRYSTALLIZATION; DRUG ANALYSIS; DRUG DESIGN; DRUG MARKETING; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FRIABILITY; HYGROSCOPY; MELTING POINT; MOLECULAR COMPLEX; PATENT; PHARMACEUTICAL CO CRYSTAL; PHYSICAL PARAMETERS; PRIORITY JOURNAL; REVIEW; SALT CO CRYSTAL; TERNARY CO CRYSTAL;

CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG DESIGN; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 84874664490     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2012.12.003     Document Type: Review

References (71)

1. J.T.A. Jones Modular and predictable assembly of porous organic molecular crystals Nature 474 2011 367 371
2. A.S. Tayi Room-temperature ferroelectricity in supramolecular networks of charge-transfer complexes Nature 488 2012 485 489
3. K-S. Huang A novel class of phenol-pyridine co-crystals for second harmonic generation J. Mater. Chem. 7 1997 713 720 (Pubitemid 127730046)
4. M.C. Etter, and S.M. Reutzel Hydrogen-bond directed cocrystallization and molecular recognition properties of acyclic imides J. Am. Chem. Soc. 113 1991 2586 2598
5. M.C. Etter Hydrogen-bond directed cocrystallization and molecular recognition properties of diarylureas J. Am. Chem. Soc. 112 1990 8415 8426
6. H.G. Brittain Cocrystal systems of pharmaceutical interest: 2010 Cryst. Growth Des. 12 2011 1046 1054
7. N. Shan, and M.J. Zaworotko The role of cocrystals in pharmaceutical science Drug Discov. Today 13 2008 440 446
8. W. Jones Pharmaceutical cocrystals: an emerging approach to physical property enhancement MRS Bull. 31 2006 875 879 (Pubitemid 44826643)
9. N. Blagden Current directions in co-crystal growth New J. Chem. 32 2008 1659 1672
10. D.J. Good, and N. Rodriguez-Hornedo Solubility advantage of pharmaceutical cocrystals Cryst. Growth Des. 9 2009 2252 2264
11. J. Wouters, and L. Quéré Pharmaceutical Salts and Co-crystals 2012 Royal Society of Chemistry
12. L.J. Barbour Concepts and nomenclature in chemical crystallography P.A. Gale, J.W. Steed, Supramolecular Chemistry from Molecules to Nanomaterials 2012 Wiley-Blackwell 2869
13. T. Friščić, and W. Jones Recent advances in understanding the mechanism of cocrystal formation via grinding Cryst. Growth Des. 9 2009 1621 1637
14. J.D. Dunitz Crystal and co-crystal: a second opinion CrystEngComm 5 2003 506 (Pubitemid 40464412)
15. J.A. Bis Hierarchy of supramolecular synthons: persistent hydroxyl...pyridine hydrogen bonds in cocrystals that contain a cyano acceptor Mol. Pharmaceut. 4 2007 401 416 (Pubitemid 46983956)
16. O. Almarsson, and M.J. Zaworotko Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? Chem. Commun. (Camb.) 17 2004 1889 1896 (Pubitemid 39335992)
17. C.B. Aakeröy, and D.J. Salmon Building co-crystals with molecular sense and supramolecular sensibility CrystEngComm 7 2005 439 448 (Pubitemid 41396867)
18. K.D.M. Harris Urea inclusion compounds J.W. Steed, J.L. Atwood, Encyclopedia of Supramolecular Chemistry 2004 Marcel Dekker
19. S.C. Nyburg, and A.R. Gerson Structures of two binary n-alkane solid solutions Acta Cryst. Sect. B 50 1994 252 256
20. G.P. Stahly Diversity in single- and multiple-component crystals. The search for and prevalence of polymorphs and cocrystals Cryst. Growth Des. 7 2007 1007 1026
21. G.P. Stahly A survey of cocrystals reported prior to 2000 Cryst. Growth Des. 9 2009 4212 4229
22. W.C. McCrone Polymorphism D. Fox, Physics and Chemistry of the Organic Solid State 1965 Interscience 726 767
23. A. Grunenberg Polymorphie und Thermische Analyse pharmazeutischer Wirkstoffe Pharm. Unserer Zeit 26 1997 224 231 (in German) (Pubitemid 27514542)
24. K.M. Anderson Designing pharmaceutical co-crystals using molecules which crystallise with Z′ > 1 Cryst. Growth. Des. 9 2009 1082 1087
25. L. Deng Ornidazole hemihydrate Acta Crystallogr. Sect. E 63 2007 o4204
26. A.V. Trask An overview of pharmaceutical cocrystals as intellectual property Mol. Pharmaceut. 4 2007 301 309 (Pubitemid 46983946)
27. C.B. Aakeröy Using cocrystals to systematically modulate aqueous solubility and melting behavior of an anticancer drug J. Am. Chem. Soc. 131 2009 17048 17049
28. D.P. McNamara Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API Pharm. Res. 23 2006 1888 1897 (Pubitemid 44200553)
29. U. Griesser The importance of solvates R. Hilfiker, Polymorphism in the Pharmaceutical Industry 2006 Wiley-VCH 225
30. McMahon, J. et al. Transform Pharmaceuticals Inc., Pharmaceutical co-crystal compositions and related methods of use, 7803786
31. D. Viterbo 2′,3′-Didehydro-3′-deoxythymidine N-methyl-2-pyrrolidone solvate (D4TNMPO) Acta Crystallogr. Sect. C 56 2000 580 581
32. S.L. Childs Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids J. Am. Chem. Soc. 126 2004 13335 13342 (Pubitemid 39382761)
33. N. Stieger Hot-stage optical microscopy as an analytical tool to understand solid-state changes in pharmaceutical materials Am. Pharm. Rev. 15 2012 32
34. D. Rossi Supramolecular constructs and thermodynamic stability of four polymorphs and a co-crystal of pentobarbital (nembutal) CrystEngComm 14 2012 2494 2506
35. A. Kofler Thermic analysis in heatable microscopes III. Announcement. Polymorphism and isomorphism phenomena in trinitro benzoyl, picric acid and alpha-trinitrotoluol Z. Phys. Chem. A 188 1941 201 228
36. D.J. Berry Applying hot-stage microscopy to co-crystal screening: a study of nicotinamide with seven active pharmaceutical ingredients Cryst. Growth Des. 8 2008 1697 1712
37. S.L. James Mechanochemistry: opportunities for new and cleaner synthesis Chem. Soc. Rev. 41 2012 413 447
38. a. Jayasankar cocrystal formation during cogrinding and storage is mediated by amorphous phase Pharm. Res. 23 2006 2381 2392 (Pubitemid 44511518)
39. T. Friščić The role of solvent in mechanochemical and sonochemical cocrystal formation: a solubility-based approach for predicting cocrystallisation outcome CrystEngComm 11 2009 418 426
40. S.A. Myz Synthesis of co-crystals of meloxicam with carboxylic acids by grinding Mendeleev Commun. 19 2009 272 274
41. N. Shan Mechanochemistry and co-crystal formation: effect of solvent on reaction kinetics Chem. Commun. (Camb.) 20 2002 2372 2373 (Pubitemid 35283628)
42. K. Fucke How good are the crystallisation methods for co-crystals? A comparative study of piroxicam New J. Chem. 36 2012 1969 1977
43. L. Padrela Formation of indomethacin-saccharin cocrystals using supercritical fluid technology Eur. J. Pharm. Sci. 38 2009 9 17
44. E.M.M. Del Valle Cyclodextrins and their uses: a review Process Biochem. 39 2004 1033 1046 (Pubitemid 38527174)
45. M.R. Caira Inclusion of the antidepressant paroxetine in β-cyclodextrin J. Incl. Phenom. Macrocycl. Chem. 46 2003 37 42
46. Y. Jin Jeon Novel molecular drug carrier: encapsulation of oxaliplatin in cucurbit[7]uril and its effects on stability and reactivity of the drug Org. Biomol. Chem. 3 2005 2122 2125
47. J.R.G. Sander A red zwitterionic co-crystal of acetaminophen and 2,4-pyridinedicarboxylic acid J. Pharm. Sci. 99 2010 3676 3683
48. J. Bernstein Polymorphism in Molecular Crystals 2nd edn 2008 Oxford University Press
49. R. Hilfiker Polymorphism: In the Pharmaceutical Industry 2006 Wiley-VCH
50. G.R. Desiraju Supramolecular synthons in crystal engineering - a new organic-synthesis Angew. Chem. Int. Ed. Engl. 34 1995 2311 2327
51. K. Fucke, and J.W. Steed X-ray and neutron diffraction in the study of organic crystalline hydrates Water 2 2010 333 350
52. S.L. Childs The salt-cocrystal continuum: the influence of crystal structure on ionization state Mol. Pharmaceut. 4 2007 323 338 (Pubitemid 46983949)
53. C.B. Aakeröy Cocrystal or salt: does it really matter? Mol. Pharmaceut. 4 2007 317 322 (Pubitemid 46983948)
54. C.B. Aakeröy Mapping out the synthetic landscape for re-crystallization, co-crystallization and salt formation CrystEngComm 12 2010 4231 4239
55. K.D.M. Harris Recent advances in the opportunities for solving molecular crystal structures directly from powder diffraction data Mol. Cryst. Liquid Cryst. 389 2002 123 129 (Pubitemid 40048731)
56. P. Gabbott Principles and Applications of Thermal Analysis 2008 Blackwell
57. A. Burger, and R. Ramberger Polymorphism of pharmaceuticals and other molecular-crystals. 1. Theory of thermodynamic rules Mikrochim. Acta 2 1979 259 271 (Pubitemid 10099836)
58. A. Burger, and R. Ramberger Polymorphism of pharmaceuticals and other molecular-crystals. 2. Applicability of thermodynamic rules Mikrochim. Acta 2 1979 273 316 (Pubitemid 10099837)
59. R.K. Harris NMR studies of organic polymorphs and solvates Analyst 131 2006 351 373
60. K.M. Anderson Structure calculation of an elastic hydrogel from sonication of rigid small molecule components Angew. Chem. Int. Ed. Engl. 47 2008 1058 1062 (Pubitemid 351204401)
61. D. Braga From unexpected reactions to a new family of ionic co-crystals: the case of barbituric acid with alkali bromides and caesium iodide Chem. Commun. (Camb.) 46 2010 7715 7717
62. D. Braga Unexpected solid-solid reaction upon preparation of KBr pellets and its exploitation in supramolecular cation complexation Chem. Commun. (Camb.) 20 2002 2302 2303 (Pubitemid 35283595)
63. Food and Drug Administration Guidance for Industry: Regulatory Classification of Pharmaceutical Co-crystals 2011 Food and Drug Administration
64. S. Aitipamula Polymorphs, salts, and cocrystals: what's in a name? Cryst. Growth Des. 12 2012 2147 2152
65. Anand, S.K. et al. Nutracryst Therapeutics Private Ltd., Pharmaceutical co-crystals of quercetin, 0258170 A1
66. M.L. Brader Hybrid insulin cocrystals for controlled release delivery Nat. Biotechnol. 20 2002 800 804 (Pubitemid 34836756)
67. N. Biswas Solid forms and pharmacokinetics J. Wouters, L. Quéré, Pharmaceutical Salts and Co-crystals 2012 Royal Society of Chemistry 128 153
68. S. Byrn Pharmaceutical solids: a strategic approach to regulatory considerations Pharm. Res. 12 1995 945 954
69. C.B. Aakeröy Crystal engineering: strategies and architectures Acta Crystallogr. Sect. B 53 1997 569 586 (Pubitemid 127439736)
70. D.E. Braun Which, if any, hydrates will crystallise? Predicting hydrate formation of two dihydroxybenzoic acids Chem. Commun. (Camb.) 47 2011 5443 5445
71. S. Mohamed Computational prediction of salt and cocrystal structures-does a proton position matter? Int. J. Pharm. 418 2011 187 198